<DOC>
	<DOCNO>NCT02160080</DOCNO>
	<brief_summary>End-stage liver disease due hepatitis C virus ( HCV ) common indication liver transplantation ( LT ) worldwide ( 30~40 % ) . Within 5 year , 25-30 % liver transplant recipient recurrent hepatitis C would progress liver cirrhosis ( Ponziani et . Al , 2011 ) , also account 2/3 graft failure death liver transplantation . ( Bzowej et al. , 2011 ) Kaohsiung Chang Gung Memorial Hospital continue least 45 HCV-related liver disease patient await liver transplantation annually . If HCV viral load significantly reduce sustain virologic response ( SVR ) achieve triple therapy Pegylated interferon alfa ( PEG ) /Ribavirin ( RBV ) /Boceprevir ( BOC ) treatment liver transplantation ( LT ) , graft re-infection HCV prevent . By way , reduce risk early fibrosis progression liver graft , hopefully , improve graft patient survival liver transplantation . ( Toniutto , 2008 ) ( Ponziani et al , 2011 ) . We aim conduct prospective , open label , single arm study . This study design single arm treat HCV patient Pegylated interferon alfa ( PEG ) /Ribavirin ( RBV ) /Boceprevir ( BOC ) triple therapy liver transplantation patient detectable HCV RNA . The total number patient would around 20 case include study take Pegylated interferon alfa ( PEG ) /Ribavirin ( RBV ) /Boceprevir ( BOC ) triple therapy . The experimental regimen contain 4 week lead-in therapy Peg-Interferon α-2b plus Ribavirin . Then , triple therapy Boceprevir + Peg-Interferon α-2b + Ribavirin use least 16 week maximal 44 week transplantation . Normal practice base treatment protocol Kaohsiung Chang Gung Memorial Hospital liver transplant center do enrollment . Patients monitor efficacy safety endpoint treatment period . HCV RNA check time transplant . Finally , patient receive regular monitoring HCV RNA 1 , 3 , 6 , 9 , 12 month liver transplantation .</brief_summary>
	<brief_title>Boceprevir Treatment Liver Pre-transplant HCV Patients</brief_title>
	<detailed_description>End-stage liver disease due hepatitis C virus ( HCV ) common indication liver transplantation ( LT ) worldwide ( 30~40 % ) . Within 5 year , 25-30 % liver transplant recipient recurrent hepatitis C would progress liver cirrhosis ( Ponziani et . Al , 2011 ) , also account 2/3 graft failure death liver transplantation . ( Bzowej et al. , 2011 ) Kaohsiung Chang Gung Memorial Hospital continue least 45 HCV-related liver disease patient await liver transplantation annually . If HCV viral load significantly reduce sustain virologic response ( SVR ) achieve triple therapy pegylated interferon alfa ( PEG ) /Ribavirin ( RBV ) /Boceprevir ( BOC ) treatment liver transplantation ( LT ) , graft re-infection HCV prevent . By way , reduce risk early fibrosis progression liver graft , hopefully , improve graft patient survival liver transplantation . ( Toniutto , 2008 ) ( Ponziani et al , 2011 ) . We aim conduct prospective , open label , single arm study . This study design single arm treat HCV patient pegylated interferon alfa ( PEG ) /Ribavirin ( RBV ) /Boceprevir ( BOC ) triple therapy liver transplantation patient detectable HCV RNA . The total number patient would around 20 case include study take pegylated interferon alfa ( PEG ) /Ribavirin ( RBV ) /Boceprevir ( BOC ) triple therapy . The experimental regimen contain 4 week lead-in therapy Peg-Interferon α-2b plus Ribavirin , follow Boceprevir + Peg-Interferon α-2b + Ribavirin least 16 week maximal 44 week transplantation . The treatment discontinue immediately time liver transplantation . Normal practice base treatment protocol Kaohsiung Chang Gung Memorial Hospital liver transplant center do enrollment . -Treatment Stopping Rules- If patient HCV RNA &gt; 100 IU/ml week 12 beginning treatment peg interferon plus ribavirin , i.e . 8 week initiation therapy boceprevir , HCV medication discontinue . If patient detectable HCV RNA Week 24 begin treatment peg interferon plus ribavirin , i.e . 20 week initiation therapy boceprevir , HCV medication discontinue . Monitoring Patients Treatment Complete blood count obtain pretreatment , Treatment Week 4 , Treatment Week 8 , thereafter , clinically appropriate . If serum hemoglobin &lt; 10 g/dL , decrease dosage ribavirin and/or administration erythropoietin ( epoetin alfa ) may warrant . -Primary Outcome Measure : Title : Number Participants Adverse Events Measure Safety Time Frame : Up time liver transplant -Secondary Outcome Measures : Title : HCV-RNA ( Hepatitis C virus RNA ) level Time Frame : Baseline , Treatment Week 12 , Treatment Week 24 . A follow-up test recommend 24 week completion treatment , time liver transplant . Finally , patient receive regular monitoring HCV RNA 1 , 3 , 6 , 9 , 12 month liver transplantation .</detailed_description>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>1 . Adult 20 year old 2 . Chronic infection genotype 1 hepatitis C virus proven positive PCR 3 . Liver cirrhosis await liver transplantation 4 . Patient compensate liver function 5 . With without hepatocellular carcinoma . 6 . Naive experienced ( failure ) HCV antiviral treatmentFailure define accord follow terminology : Relapsing patient : HCV RNA undetectable end treatment , become detectable discontinuation treatment Breakthrough : increase viremia 1 log treatment Nonresponding patient partial response : HCV RNA detectable W24 without ever undetectable decrease HCV RNA ≥ 2 log W12 Nonresponding patient null response : decrease HCV RNA &lt; 2 log W12 7 . No need prior treatment washout 8 . Written patient inform consent 1 . Non control sepsis 2 . Platelets &lt; 50,000/mm3 3 . Neutrophil granulocyte level &lt; 1000/mm3 4 . Creatinine clearance &lt; 50 mL/min 5 . Hb &lt; 10 g/dL 6 . Uncontrolled psychiatric problem 7 . Hypersensitivity contraindication component boceprevir formulation 8 . Contraindication interferon ribavirin 9 . HIV coinfection 10 . HBV coinfection ( unless treat effectively analogue , proven undetectable viremia least 12 month ) 11 . Other infectious disease underway 12 . Neoplastic disease hepatocellular carcinoma previous year , neoplastic disease prognosis le 3 year 13 . Treatment immunosuppressor ( include corticosteroid ) , antiviral study , except aciclovir 14 . Current anticipate use follow prohibited medication : midazolam , pimozide , amiodarone , flecainide , propafenone , quinidine , ergot derivative 15 . Person participate another study include exclusion period still underway preenrollment 16 . Pregnancy , breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Boceprevir ;</keyword>
	<keyword>Liver pre-transplant</keyword>
</DOC>